Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Passes Below 50 Day Moving Average – Time to Sell?

Posted by on May 20th, 2026

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report)’s share price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $11.28 and traded as low as $11.02. Bayer Aktiengesellschaft shares last traded at $11.05, with a volume of 972,243 shares trading hands.

Analyst Upgrades and Downgrades

BAYRY has been the topic of a number of recent research reports. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Friday, May 8th. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Finally, DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 9th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Bayer Aktiengesellschaft currently has a consensus rating of “Buy”.

Check Out Our Latest Research Report on BAYRY

Bayer Aktiengesellschaft Trading Up 0.3%

The stock has a market capitalization of $43.43 billion, a P/E ratio of -17.27, a P/E/G ratio of 3.57 and a beta of 0.62. The company has a quick ratio of 0.63, a current ratio of 1.01 and a debt-to-equity ratio of 1.22. The stock’s 50 day moving average price is $11.28 and its 200-day moving average price is $11.04.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.15. The company had revenue of $15.73 billion during the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.74%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, equities research analysts expect that Bayer Aktiengesellschaft will post 1.24 earnings per share for the current year.

About Bayer Aktiengesellschaft

(Get Free Report)

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.

Featured Articles

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.